{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:33:37Z","timestamp":1793291617500,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":198,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Salvage radiotherapy (SRT) is the standard of care for patients with biochemical recurrence (BCR) after radical prostatectomy (RP). Several randomized trials have evaluated the addition of hormonal therapy (HT), including androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs), to SRT; however, differences in patient selection, treatment duration, and endpoints have led to inconsistent results. We performed an updated systematic review and meta-analysis to clarify the clinical benefit of adding HT to SRT in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search of PubMed\/MEDLINE, EMBASE, the Cochrane Library, ClinicalTrials.gov, and ASCO and ESMO meeting abstracts was conducted through April 2025. Randomized phase II-III trials enrolling patients with confirmed BCR after RP and comparing SRT with or without HT were included. Five trials (GETUG-AFU 16, RTOG 9601, RTOG 0534\/SPPORT, RADICALS-HD, and SALV-ENZA), comprising 4536 patients, met the eligibility criteria. Hazard ratios (HRs) and 95% confidence intervals (CIs) for metastasis-free survival (MFS), progression-free survival (PFS), biochemical progression-free survival (bPFS), and overall survival (OS) were pooled using fixed- or random-effects models according to heterogeneity. Analyses were stratified by HT duration (short-term vs. long-term), and subgroup analyses were performed based on pathological features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Short-term HT combined with SRT significantly improved bPFS (HR\u2009=\u20090.57; 95% CI: 0.46\u20130.71,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001), PFS (HR\u2009=\u20090.58; 95% CI: 0.49\u20130.69;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001), and MFS (HR\u2009=\u20090.82; 95% CI: 0.69\u20130.96;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Long-term HT was also associated with improved MFS (HR\u2009=\u20090.76; 95% CI: 0.61\u20130.94;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). No statistically significant OS benefit was observed with either short-term or long-term HT. Subgroup analyses showed a significant MFS benefit in patients with positive surgical margins (HR\u2009=\u20090.68; 95% CI: 0.47\u20130.98;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04), whereas no clear benefit was detected in patients with Gleason score \u22658 or negative margins.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The addition of HT to SRT improves disease control outcomes in patients with BCR after RP, particularly in those with positive surgical margins, although no overall survival benefit was demonstrated. These findings support a tailored approach to treatment intensification in the salvage setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41391-026-01120-9","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T07:02:02Z","timestamp":1779087722000},"page":"951-957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Salvage radiotherapy with or without hormonal therapy for biochemical recurrence after radical prostatectomy: A systematic review and meta-analysis"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7991-8819","authenticated-orcid":false,"given":"Fortuna","family":"Migliaccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano","family":"Flauto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Barraco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Neola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Chioccola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Facchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Servetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Formisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"1120_CR1","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/JU.0000000000003891","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage Therapy for Prostate Cancer: AUA\/ASTRO\/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy. J Urol. 2024;211:518\u201325.","journal-title":"J Urol"},{"key":"1120_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. Eur Urol. 2019;75:967\u201387.","journal-title":"Eur Urol"},{"key":"1120_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, Van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II- 2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86:164\u201382.","journal-title":"Eur Urol"},{"key":"1120_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396:1413\u201321.","journal-title":"Lancet"},{"key":"1120_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non- inferiority trial. Lancet Oncol. 2020;21:1331\u201340.","journal-title":"Lancet Oncol"},{"key":"1120_CR6","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","volume":"396","author":"CL Vale","year":"2020","unstructured":"Vale CL, Fisher D, Kneebone A, Parker C, Pearse M, Richaud P, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;396:1422\u201331.","journal-title":"Lancet"},{"key":"1120_CR7","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.juro.2016.08.106","volume":"197","author":"A Abugharib","year":"2017","unstructured":"Abugharib A, Jackson WC, Tumati V, Dess RT, Lee JY, Zhao SG, et al. Very Early Salvage Radiotherapy Improves Distant Metastasis-Free Survival. J Urol. 2017;197:662\u20138.","journal-title":"J Urol"},{"key":"1120_CR8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","volume":"3","author":"WR Polkinghorn","year":"2013","unstructured":"Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3:1245\u201353.","journal-title":"Cancer Discov"},{"key":"1120_CR9","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1158\/0008-5472.CAN-15-0892","volume":"75","author":"DE Spratt","year":"2015","unstructured":"Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, et al. Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res. 2015;75:4688\u201396.","journal-title":"Cancer Res"},{"key":"1120_CR10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","volume":"3","author":"JF Goodwin","year":"2013","unstructured":"Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 2013;3:1254\u201371.","journal-title":"Cancer Discov"},{"key":"1120_CR11","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magn\u00e9 N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, et al. Short- term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20:1740\u20139.","journal-title":"Lancet Oncol"},{"key":"1120_CR12","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1607529","volume":"376","author":"WU Shipley","year":"2017","unstructured":"Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, et al. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med. 2017;376:417\u201328.","journal-title":"N Engl J Med"},{"key":"1120_CR13","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1200\/JCO.21.02741","volume":"40","author":"WC Jackson","year":"2022","unstructured":"Jackson WC, Tang M, Schipper MJ, Sandler HM, Zumsteg ZS, Efstathiou JA, et al. Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology\/RTOG 9601. J Clin Oncol. 2022;40:3172\u20139.","journal-title":"J Clin Oncol"},{"key":"1120_CR14","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399:1886\u2013901.","journal-title":"Lancet"},{"key":"1120_CR15","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","volume":"403","author":"CC Parker","year":"2024","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, et al. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS- HD randomised controlled trial. Lancet. 2024;403:2405\u201315.","journal-title":"Lancet"},{"key":"1120_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.eururo.2024.07.026","volume":"86","author":"CC Parker","year":"2024","unstructured":"Parker CC, Clarke NW, Cook AD, Petersen PM, Catton CN, Cross WR, et al. Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047). Eur Urol. 2024;86:422\u201330.","journal-title":"Eur Urol"},{"key":"1120_CR17","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1200\/JCO.22.01662","volume":"41","author":"PT Tran","year":"2023","unstructured":"Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, et al. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High- Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. J Clin Oncol. 2023;41:1307\u201317.","journal-title":"J Clin Oncol"},{"key":"1120_CR18","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"1120_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210.","journal-title":"Syst Rev"},{"key":"1120_CR20","unstructured":"Review Manager 5 (RevMan [Computer program]. Version 5.4. Copenhagen: The Cochrane Collaboration, 2020."},{"key":"1120_CR21","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"1120_CR22","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"1120_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388.","journal-title":"Control Clin Trials"},{"key":"1120_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1\u201312.","journal-title":"Control Clin Trials"},{"key":"1120_CR25","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.","journal-title":"BMJ"},{"key":"1120_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jphys.2020.07.003","volume":"67","author":"CX Xie","year":"2021","unstructured":"Xie CX, Machado GC. Clinimetrics: Grading of Recommendations, Assessment, Development and Evaluation (GRADE). J Physiother. 2021;67:66.","journal-title":"J Physiother"},{"key":"1120_CR27","unstructured":"Burdett S, Fisher DJ, Tierney JF, Cook AD, Spratt DE, Dignam JJ, et al. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for nonmetastatic prostate cancer: a collaborative systematic review and meta-analysis of aggregate data. Eur Urol. 2025: S0302-283800291-X."},{"key":"1120_CR28","first-page":"00131","volume":"S2588-9311","author":"QC Le","year":"2025","unstructured":"Le QC, Siech C, Hoeh B, Saad F, Preisser F, Tilki D, et al. Influence of Concomitant Androgen Deprivation Therapy and Its Duration for Salvage Radiation After Radical Prostatectomy: A Systematic Review and Network Meta-analysis According to Published Data. Eur Urol Oncol. 2025;S2588-9311:00131\u20132.","journal-title":"Eur Urol Oncol"},{"key":"1120_CR29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","volume":"67","author":"PL Nguyen","year":"2015","unstructured":"Nguyen PL, Alibhai SM, Basaria S, D\u2019Amico AV, Kantoff PW, Keating NL, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67:825\u201336.","journal-title":"Eur Urol"},{"key":"1120_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bju.16484","volume":"134","author":"C Gonz\u00e1lez-San Segundo","year":"2024","unstructured":"Gonz\u00e1lez-San Segundo C, L\u00f3pez Campos F, G\u00f3mez Iturriaga A, Rodr\u00edguez A, Olivera J, Duque-Santana V, et al. A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24. BJU Int. 2024;134:568\u201377.","journal-title":"BJU Int"},{"key":"1120_CR31","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.eururo.2014.10.036","volume":"67","author":"EA Klein","year":"2015","unstructured":"Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, et al. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. Eur Urol. 2015;67:778\u201386.","journal-title":"Eur Urol"},{"key":"1120_CR32","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1200\/JCO.2012.46.4396","volume":"31","author":"MR Cooperberg","year":"2013","unstructured":"Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S, et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013;31:1428\u201334.","journal-title":"J Clin Oncol"},{"key":"1120_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.euf.2021.03.015","volume":"8","author":"M Covas Moschovas","year":"2022","unstructured":"Covas Moschovas M, Chew C, Bhat S, Sandri M, Rogers T, Dell\u2019Oglio P, et al. Association Between Oncotype DX Genomic Prostate Score and Adverse Tumor Pathology After Radical Prostatectomy. Eur Urol Focus. 2022;8:418\u201324.","journal-title":"Eur Urol Focus"},{"key":"1120_CR34","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/pros.24150","volume":"81","author":"JP Corradi","year":"2021","unstructured":"Corradi JP, Cumarasamy CW, Staff I, Tortora J, Salner A, McLaughlin T, et al. Identification of a Five Gene Signature to Predict Time to Biochemical Recurrence After Radical Prostatectomy. Prostate. 2021;81:694\u2013702.","journal-title":"Prostate"},{"key":"1120_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216739","volume":"588","author":"W Yin","year":"2024","unstructured":"Yin W, Chen G, Li Y, Li R, Jia Z, Zhong C, et al. Identification of a 9-Gene Signature to Enhance Biochemical Recurrence Prediction in Primary Prostate Cancer: A Benchmarking Study Using Ten Machine Learning Methods and Twelve Patient Cohorts. Cancer Lett. 2024;588:216739.","journal-title":"Cancer Lett"},{"key":"1120_CR36","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.ijrobp.2025.08.028","volume":"123","author":"DE Spratt","year":"2025","unstructured":"Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JP, et al. LBA 04: A Double-Blinded Placebo-Controlled Biomarker Stratified Randomized Trial of Apalutamide (APA) and Radiotherapy for Recurrent Prostate Cancer (NRG GU006, BALANCE trial). Int J Radiat Oncol Biol, Phys. 2025;123:1197\u20138.","journal-title":"Int J Radiat Oncol Biol, Phys"},{"key":"1120_CR37","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/bju.13367","volume":"118","author":"NP Murray","year":"2016","unstructured":"Murray NP, Aedo S, Reyes E, Orellana N, Fuentealba C, Jacob O. Prediction Model for Early Biochemical Recurrence After Radical Prostatectomy Based on the Cancer of the Prostate Risk Assessment Score and the Presence of Secondary Circulating Prostate Cells. BJU Int. 2016;118:556\u201362.","journal-title":"BJU Int"},{"key":"1120_CR38","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/JU.0000000000003892","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage Therapy for Prostate Cancer: AUA\/ASTRO\/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence After Radical Prostatectomy. J Urol. 2024;211:509\u201317.","journal-title":"J Urol"},{"key":"1120_CR39","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1001\/jamaoncol.2025.3746","volume":"11","author":"C Belliveau","year":"2025","unstructured":"Belliveau C, Saad F, Duplan D, Petit C, Delouya G, Taussky D, et al. Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy. JAMA Oncol. 2025;11:1431\u20138.","journal-title":"JAMA Oncol"},{"key":"1120_CR40","doi-asserted-by":"crossref","unstructured":"Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved survival with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2026;394:563\u201375.","DOI":"10.1056\/NEJMoa2510310"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01120-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01120-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:03:08Z","timestamp":1793289788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01120-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01120-9","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Roberto Bianco served as a consultant and an advisory board member for BMS, MSD, Pfizer, AstraZeneca, Lilly, and Novartis outside the submitted work. Alberto Servetto reports speaker honoraria from Eli Lilly, MSD, Janssen, Roche, Novartis, and Gilead; travel support from Bristol-Myers Squibb and AstraZeneca; and being a board advisor for MSD outside the submitted work. Luigi Formisano served as a consultant and an advisory board member for Seagen, Amgen, BMS, MSD, Janssen, and Pierre Fabre Pharma outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}